Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin

Name: Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin
License: Public Domain

AstraZeneca

ClinicalTrials.gov · Datasets · License: Public Domain

Open Source ↗

muscle invasive bladder cancer

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 481759
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.